Drug company issues warning about flu drugBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7231.334/b (Published 05 February 2000) Cite this as: BMJ 2000;320:334
View Full Text
- Gavin Yamey
GlaxoWellcome issued a warning letter to doctors across Europe last week that its drug for treating influenza, zanamivir (Relenza), could cause bronchospasm and serious respiratory deterioration.
The company now advises doctors to use special caution in prescribing the drug to patients with underlying asthma or chronic obstructive pulmonary disease. Such patients, it suggests, should …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.